Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-positive Metastatic Breast Cancer
Interventions: DRUG: Alpelisib|DRUG: Tucatinib|DRUG: Fulvestrant
Sponsor: Criterium, Inc.
Collaborators: Novartis|Seagen Inc.